Stimulation of iron(II) bleomycin activity by phosphate-containing compounds.
Orthophosphate and phosphate derivatives including pyrophosphate, hexametaphosphate, ATP, ADP, and inositol hexaphosphate enhance the extent of DNA degradation by iron(II) bleomycin. These phosphate-containing compounds increase both the release of free nucleic base and that of base propenals which are DNA cleavage products, probably by enhancing the efficiency with which Fe(II) is recruited into the drug. Phosphate action occurs during drug activation prior to the attack on DNA. In addition, phosphates affect the stability of the activated drug complex, overcome the inhibition observed with high concentrations of DNA, and reduce the size of the DNA fragment necessary for reacting with the drug. Phosphate derivatives bind to iron(II) bleomycin and alter its optical spectrum. An analysis of titration data for pyrophosphate and inositol hexaphosphate indicates that each phosphate compound binds to more than one iron(II) bleomycin molecule. With ATP, ADP, and 2,3-diphosphoglycerate, only a single phosphate-containing compound binds to the ferrous drug complex. The affinity for ATP is sufficiently high as to suggest that the ternary complex formed in vitro may exist physiologically.
R M
RM
Burger
S B
SB
Horwitz
J
J
Peisach
D000244:Adenosine Diphosphate / Q000494:pharmacology*; D000255:Adenosine Triphosphate / Q000494:pharmacology*; D000818:Animals; D001761:Bleomycin / Q000494:pharmacology* / Q000031:analogs & derivatives; D002417:Cattle; D004247:DNA / Q000378:metabolism*; D004269:DNA, Bacterial / Q000378:metabolism; D007700:Kinetics; D010710:Phosphates / Q000494:pharmacology*; D010833:Phytic Acid / Q000494:pharmacology*; D010957:Plasmids; D013211:Staphylococcus aureus / Q000235:genetics; D013950:Thymus Gland
D004269:DNA, Bacterial; D010710:Phosphates; C023503:iron bleomycin; D001761:Bleomycin; D000244:Adenosine Diphosphate; D010833:Phytic Acid; D000255:Adenosine Triphosphate; D004247:DNA